NCM
LENZ

Nantahala Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Nantahala Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-117,282
Closed -$2.15M – 146
2023
Q4 		$2.15M Buy
+117,282
New +$1.94M 0.13% 86

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Nantahala Capital Management's LENZ Position: Q1 2024 in Review

Nantahala Capital Management sold out of LENZ Therapeutics (LENZ) in Q1 2024, closing a stake of 117,282 shares — an estimated $2.15M sold.

Nantahala Capital Management first reported a position in LENZ in Q4 2023 and held it in 1 quarter. The position peaked at $2.15M in Q4 2023. 55 funds tracked by Wall St. Rank hold LENZ as of Q1 2024.

  • Nantahala Capital Management reported no remaining LENZ Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Nantahala Capital Management sold 117,282 LENZ Therapeutics shares in Q1 2024, an estimated $2.15M.
  • Nantahala Capital Management first reported a position in LENZ Therapeutics in Q4 2023 and held it in 1 quarter.
  • Nantahala Capital Management's LENZ Therapeutics position peaked at $2.15M in Q4 2023.
  • 55 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2024.

Based on Nantahala Capital Management's 13F filing for Q1 2024, filed 15 May 2024.